ADAR1 Adds 922,849 Tenax Shares for $1.46M, Lifting Stake to 7.45M
TENX sits 24% above its 52-week low of $1.31 on light trading volume (0.3× avg).
Summary
ADAR1 Capital bought 922,849 Tenax shares for $1.46 million over three days, raising its stake to 7.45 million shares — the latest tranche in a steady post-trial-miss accumulation.
Key Events · Ownership and Investor Activity · TENX
-
ADAR1 Buys 922,849 Shares for $1.46M
Three open-market purchases from 2026-10-19 to 2026-10-21 at weighted-average prices of $1.5066, $1.5952 and $1.6588.
-
Stake Rises to 7,447,000 Shares
Post-transaction holdings of 7,447,000 shares, up from the 6.5 million reported on 2026-09-08.
-
Fourth Tranche Since Trial Miss
Follows $1.81M bought from 2026-08-24 and $1.38M from 2026-09-02, all after the 2026-08-10 Phase 3 LEVEL primary-endpoint miss.
-
Timing After LEVEL-2 Pause
Purchases came after the 2026-10-08 8-K pausing LEVEL-2 enrollment for a protocol amendment and an FDA Type C meeting request.
Analysis · TENX · Life Sciences
ADAR1 Capital Management, the 10% owner managed by Daniel Schneeberger, bought 922,849 Tenax shares for $1,463,426 over three days at weighted-average prices of $1.5066, $1.5952 and $1.6588 — the purchases stepped up in price each day. Holdings now stand at 7,447,000 shares, up from the 6.5 million reported on 2026-09-08. This is the fourth disclosed accumulation tranche since the Phase 3 LEVEL trial missed its primary endpoint on 2026-08-10, and it comes after the 2026-10-08 8-K pausing LEVEL-2 enrollment to amend the protocol and request an FDA Type C meeting. A financial investor buying into a post-miss selloff is a conviction vote, but it is a 10% owner rather than an operator, so it carries less weight than an executive purchase would.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61M. The 52-week trading range was $1.31 to $19.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.